甘李药业(603087.SH)：目前公司与山德士的合作仍在持续稳步推进

Core Viewpoint - The collaboration between the company and Sandos, established in 2018, is progressing steadily, focusing on the commercialization of three biosimilars in the European and American markets [1] Group 1: Partnership and Agreements - The company signed a commercial and supply agreement with Sandos in 2018, which stipulates that Sandos will handle the commercialization of three biosimilars (insulin glargine, insulin aspart, and insulin lispro) upon their approval [1] - The partnership remains active and is advancing as planned [1] Group 2: Product Approval and Market Strategy - The company's insulin glargine injection received marketing authorization from the European Commission on January 15, 2026 [1] - Currently, the product is in the pre-commercialization phase, focusing on market access, channel development, and logistics preparation [1] - The company emphasizes the importance of the European market as a strategic target and views this approval as a significant step in its internationalization strategy [1]